InnoModels Biotechnology, an innovative company dedicated to advancing biomedical research and clinical therapeutics, provides powerful support for cancer research and drug development through its CDX (Cancer-Derived Xenograft) modeling platform. The platform is not only rich in experimental capabilities, but also has the unique advantage of providing scientists with efficient and precise tools to study the biology of cancer and its application in therapeutic areas in depth.
First of all, the CDX model platform of InnoModels Biotechnology has a huge library of tumor cell lines. Over 500 validated tumor cell lines are available, covering a wide range of cancer types and subtypes. This enables researchers to select the most suitable cell lines for their research area, ensuring the accuracy and reliability of their experiments. At the same time, InnoModels Biotechnology also has more than ten years of experience in experimental design and management, and its team consists of experienced specialists who have deep expertise and practical experience in the field of CDX modeling. From experimental design, problem solving to data interpretation, InnoModels' team of experts is committed to ensuring that the research is on the right track.

In addition to a large library of tumor cell lines and rich experimental experience, the CDX modeling platform of InnoModels Biotechnology also focuses on the integrity and traceability of experimental data. All cells are tested for STR and Mycoplasma and Chlamydia to ensure cell growth stability and experimental reliability. In addition, the platform maintains thorough and traceable experimental records, enabling researchers to easily meet reporting and documentation standards to ensure the safety and compliance of research data.
It is worth mentioning that on top of the CDX model platform, InnoModels Biotechnology has also introduced the firefly luciferase (Luc) labeled CDX model, which allows in situ inoculation with in vivo imaging monitoring. This model helps to study tumor metastasis, the ability of drugs to cross the blood-brain barrier, etc., providing a more intuitive and precise tool for drug development. In addition, InnoModels Biotechnology has also independently developed NIG mice, which have a high level of innate immunity and are more tolerant to BAF3 engineered cell lines than other mouse breeds, and thus can be more effectively used for in vivo efficacy testing of BAF3 engineered cell lines.
In the field of cancer research, CDX technology is a cancer tissue-based xenotransplantation technique. Cancer models are created by transplanting a patient's cancer tissue into an animal, such as a mouse, to form a human-derived xenograft tumor. The core of this technology is that it preserves the heterogeneity and complexity of the original tumor tissue, providing a more realistic and reliable platform for research. The CDX modeling platform of InnoModels Biotechnology is based on this technology, providing scientists with a powerful research tool to advance cancer research and drug development.
In short, with its large tumor cell line library, rich experimental experience, rigorous data management and innovative technology, the CDX modeling platform of InnoModels Biotechnology has become a leader in the field of biomedical research and cancer treatment. The platform provides scientists with efficient and precise tools to help them deeply study the biological characteristics of cancer and its application in the field of treatment. In the future, with the continuous progress and innovation of technology, the CDX modeling platform of InnoModels will continue to lead the way of innovation in biomedical research and cancer treatment.